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Tyrosine kinases are important for the development of
pathological angiogenesis, a critical factor for survival and
proliferation of tumor cells. Inhibition of tyrosine kinases
either through targeted binding of its ligands or inhibition of
its receptor has led to significant hindrance in angiogenesis
and has improved survival for several cancers. Several of
these antibodies or small molecules have been approved for
treatment of recurrent and resistant cancers over the last
decade. Although generally well tolerated, tyrosine kinase
inhibitors have been linked with development of
hypertension and proteinuria. We review the literature for
incidence and severity of hypertension and proteinuria
among several tyrosine kinase inhibitors, their
pathophysiologic mechanisms, and provide a guide for
screening and management.
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Tyrosine kinase inhibitors (TKIs) are a new class of
antineoplastic drugs used in treatment of solid organ cancers,
such as those of colon, breast, lung, and kidney among
several others either alone or in combination with other
chemotherapy agents. Although overall well tolerated, they
are still limited in their use by significant toxicities, some
of which are relevant for the practicing nephrologist. Protein-
uria and hypertension have been recognized as major side
effects. Although uncommon, the severity of these conditions
and the rapidity of onset can be alarming. With improved
survival and outcomes for cancer treatments, it is critical to
identify these side effects. Management of these side effects
may improve overall outcomes. The purpose of this review is
to increase awareness and review the pathophysiological
mechanisms of these side effects.
TYROSINE KINASE
Tyrosine kinases belong to the family of protein kinases and are
classified in two broad categories: receptor tyrosine kinases
(RTKs) and cytoplasmic tyrosine kinases. More than half of the
90 tyrosine kinases identified are RTKs. RTKs on binding with
a ligand undergo dimerization and catalyze phosphorylation of
tyrosine residues on proteins by using ATP. Such phosphoryla-
tion causes a change in the function of the cytoplasmic
proteins. Several of these proteins mediate secondary effects by
their action at the genetic transcription level. These can result
in changes in enzyme activity, cell growth, differentiation,
metabolism, adhesion, motility, and death.1 Mutations leading
to overactivity of tyrosine kinases can lead to development of
cancers.2 Accordingly, targeting RTKs or their ligands is an
attractive option for treatment of many cancers.
TYROSINE KINASE INHIBITORS
Imatinib was the first TKI used to treat chronic myelogenous
leukemia as it targeted the specific bcr–abl, a cytoplasmic
tyrosine kinase, along with RTKs for platelet-derived growth
factor receptor and c-kit. This was followed by the discovery
of inhibitors to other RTKs, such as gefitinib and panitu-
mumab for epidermal growth factor and bevacizumab and
ranibizumab for vascular endothelial growth factor (VEGF).
These were monoclonal antibodies directed against RTK
ligands. With further improvements in drug discovery,
monoclonal antibodies are being replaced by orally available
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molecules that targeted RTKs directly. These molecules in
addition are capable of inhibiting multiple RTKs simulta-
neously. Examples of orally administered RTK inhibitors
include sorafenib, sunitinib, dasatinib, and pazopanib, among
several others (Table 1). Recently completed phase III trials for
several of these inhibitors have led to Food and Drug
Administration approval for their use in treatment of several
advanced cancers. These include, but are not limited to, cancers
of liver (sorafenib 2007), kidney (sorafenib 2005, sunitinib
2006, and pazopanib 2009), gastrointestinal stromal tumor
(sunitinib 2006), lung (erlotinib 2004), pancreas (erlotinib
2005), and chronic myelogenous leukemia (dasatinib 2010).
TKIs: mechanism of action
TKIs inhibit angiogenesis. Angiogenesis, a limited and
regulated process in healthy individuals, is pivotal for survival
and proliferation of tumor cells. The regulation of angiogen-
esis is complicated. Several growth factors such as VEGF,
epidermal growth factor, and platelet-derived growth factor
cause angiogenesis. Before these growth factors can cause
angiogenesis, RTKs must activate them. Other regulators of
angiogenesis include transcription factors such as hypoxia-
inducible factor, mitogen-activated protein kinase, and
phosphoinositide 3-kinase signaling.2 Tumor cells either
secrete growth factors or auto-activate RTKs through
mutations, leading to a favorable proangiogenic over
antiangiogenic milieu. Inhibitions through targeted actions
on ligands or RTKs lead to potent antiproliferative effects by
inhibiting pathological angiogenesis.
In comparison with other antineoplastic drugs, TKIs have
few adverse events; two important and sometimes severe side
effects of TKIs are proteinuria and hypertension.
Pathophysiology and proposed mechanisms for
proteinuria with TKIs
Understanding the pathophysiology of proteinuria requires
the understanding of the glomerular filtration barrier (GFB).
GFB is made up of the fenestrated endothelium, glomerular
basement membrane, and podocytes, which form the slit
diaphragm. Together, they provide an effective barrier to
prevent loss of large molecules and proteins. The foot
processes of the podocytes are connected together by a slit
diaphragm or membrane. The integrity of the slit diaphragm
is maintained by several proteins made by the podocytes,
which include nephrin, Neph1, FAT, podocin, and CD2-
associated protein (CD2AP) among others. Inactivation of
these protein genes in mice causes massive proteinuria, and
sometimes the absence of a slit diaphragm and death.3
Among these proteins, nephrin production has been shown
to be selectively inhibited with VEGF inhibition.4 Recent
studies in genetically modified mice suggest that podocyte-
derived VEGF has a major role in the development of the
endothelium and the maintenance of its fenestrations. To
determine the role of VEGF in development and maintenance
of the GFB, Eremina et al.5 generated mice with gain and loss
of function specifically involving the podocytes. When VEGF
gene was deleted in a homozygotic manner, mice died at
birth or within 18 h with hydrops and kidney failure. When
the gene was deleted in a heterozygotic manner, it resulted in
renal disease by 2.5 weeks. Grossly, the kidneys appeared to
be smaller and paler, and had higher creatinine and urea with
lower hemoglobin. Renal biopsies revealed significant
endotheliosis, defects in endothelial migration, and differ-
entiation with loss of GFB. These findings were similar to
those seen in preeclampsia. At 6.5 weeks and 9 weeks,
endothelial cells became necrotic and podocyte foot processes
were completely lost.5 This confirmed the critical role of
VEGF in the development of GFB. In a later study, Eremina
et al.6 were again able to show similar findings in selective
VEGF knockout mice, confirming the role of VEGF not only
in development but also in maintenance of GFB.
One may be tempted to speculate that replacement of
VEGF may be of therapeutic value. However, overexpression
of VEGF is also deleterious. When kidneys of mice with gain-
of-function VEGF 164 expression were examined, significant
surface hemorrhages were noted and renal biopsies revealed
collapsing glomerulopathy as seen in HIV.5 This similarity is
interesting because HIV produces a TAT protein that signals
through flk1 in the endothelial cells of Kaposi’s sarcoma.
Further the podocyte is a major reservoir of HIV.7 These
findings may potentially explain the pathology seen in HIV-
associated collapsing focal segmental glomerulosclerosis, that
is, possible VEGF overexpression.
On the basis of these findings, it is thought that VEGF
produced by podocytes travels across the GFB and reaches
the endothelial surfaces where it interacts with several
receptors such as Flk1 (VEGF receptor 1) and Flt1 (VEGF
receptor 2). This may also partly explain the proximity of the
podocytes to the vascular cleft in the development of kidney.
In fact, it is highly likely that VEGF may be the signal that
localizes endothelial cells of the vascular cleft to the
podocytes forming the glomerular basement membrane.
The similarities to pathological findings in preeclampsia may
Table 1 | TKIs currently available
Name Target receptor Type of TKI
Bevacizumab VEGF Monoclonal antibody
Cetuximab Erb1 Monoclonal antibody
Trastuzumab Erb2 Monoclonal antibody
Ranibizumab VEGF Monoclonal antibody
Panitumumab EGFR Monoclonal antibody
Pegaptanib VEGF RNA aptamer
Gefitinib EGFR Small molecule
Imatinib Bcr–abl Small molecule
Sorafenib Multiple targets Small molecule
Dasatinib Multiple targets Small molecule
Sunitinib Multiple targets Small molecule
Erlotinib Erb1 Small molecule
Nilotinib Bcr–abl Small molecule
Lapatinib Erb1/Erb2 Small molecule
Pazopanib VEGFR2/PDGFR/c-kit Small molecule
Crizotinib ALK Small molecule
Abbreviations: ALK, anaplastic lymphoma kinase; Erb/EGFR, epidermal growth factor
receptor; PDGFR, platelet-derived growth factor receptor; TKI, tyrosine kinase
inhibitor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
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similarly be explained by increased soluble flt1.8 As
mentioned earlier, flt1 are VEGF receptors, and abnormal
generation of these soluble forms of receptors by the placenta
leads to binding of VEGF generated at the podocytes (as they
are one of the largest VEGF-producing cells). Although
administration of VEGF reversed glomerular finding in
pregnant rats in this study and in experimental models of
glomerulonephritis9 and thrombotic microangiopathy
(TMA),10 Eremina et al.6 did not find reversal of renal
pathology in knockout mice that were made deficient in
VEGF by conditional gene deletions.
Some of the other mechanisms proposed for development
of proteinuria have been due to development of hypertension
and the use of concomitant agents such as gemcitabine,
interferon-a, and bisphosphonates, most notably pamidro-
nate.11 However, hypertension is unlikely to explain the
development of proteinuria completely. In a study of
bevacizumab in metastatic renal cell carcinoma, proteinuria
only partly correlated with hypertension. A total of 54% of
patients with grade 2 or 3 hypertension and 16% of patients
with grade 0 or 1 developed proteinuria.12 Although the
gradation partly explains the contribution of hypertension, it
does not completely explain development of proteinuria. The
variable incidence of proteinuria among patients receiving
TKIs highlights the possibility of differences in susceptibility
for developing proteinuria, ranging from genetic make up to
preexisting comorbid conditions, concomitant drugs, and
type of cancer. Further studies are needed in order to
understand these susceptibilities. Figure 1 demonstrates our
current understanding of the pathophysiology of TKI-
induced proteinuria and hypertension.
Proteinuria and hypertension with TKIs
Proteinuria. Proteinuria has now been strongly linked
to adverse cardiovascular outcomes and progression to
end-stage renal disease in patients with chronic kidney
disease.13,14 Although the first line of management of
proteinuria is to use drugs to reduce proteinuria (such as
angiotensin-converting enzyme inhibitors), the more effec-
tive way to manage this condition is by treating or removing
the offending condition or agent. TKIs, specifically those
directed against VEGF, are associated with development of
proteinuria. Proteinuria was first reported in the prototypical
VEGF inhibitor—bevacizumab. A meta-analysis of seven
trials involving 1850 patients revealed an increased risk of
proteinuria with the use of bevacizumab. This was noted to
be dose dependent (relative risk (RR) of 1.4 with low dose
(95% confidence interval (CI): 1.1–1.7) and RR of 2.2 with
high dose (95% CI: 1.6–2.9)). Overall incidence of proteinuria
ranged from 21 to 41% in the low-dose group and 22 and
63% in high-dose group.15 However, only 1–1.8% developed
grade III proteinuria or worse. This review was limited by
heterogeneity in the following characteristics that can have an
important effect on proteinuria: patient populations, doses
of bevacizumab, tumor types, chemotherapies, and lengths
of treatment. The most important limitation of this
meta-analysis was that measurement of proteinuria in some
studies was based on urine dipstick testing instead of the
more quantitative protein/creatinine ratio or 24-h urine
collections. In a more recent follow-up review by the same
authors of more than 12,000 patients, Wu et al.16 identified
the incidence of high-grade proteinuria (grade 3 or worse) at
2.2% with a RR of 4.79 (95% CI: 2.71–8.46). The RR of
developing nephrotic syndrome with chemotherapy contain-
ing bevacizumab (when compared with chemotherapy
without bevacizumab) was 7.78 (ref. 16). Renal cell cancers
tended to have an increased risk of proteinuria compared
with other cancers.16 Several of the trials reporting data on
proteinuria from major cancer studies did so using the
National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (Table 2). This classification has
inherent limitations in interpretation and needs to be
analyzed further for application in renal outcomes and
assessment of proteinuria.
Information regarding proteinuria with newer generation of
TKIs, many of which are orally active drugs instead of
monoclonal antibodies, is limited. Sunitinib17,18 and sorafenib19
have been reported to cause proteinuria in case reports.
Pazopanib has been more widely linked to the development
of proteinuria. In a phase I trial involving 63 patients with
advanced-stage refractory solid tumors, Hurwitz et al.20
identified proteinuria with pazopanib in 5% of the patients
Tyrosine kinase
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Nitric oxide
inhibition
VEGF
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Hypertension Proteinuria
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resistance
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Figure 1 |Postulated mechanisms for the development of
proteinuria and hypertension with tyrosine kinase inhibitors
(TKIs). TKIs, by inhibiting nitric oxide production in the
endothelium, increase vascular resistance and cause hypertension.
By inhibiting vascular endothelial growth factor (VEGF), TKIs
reduce nephrin production. Nephrin is important to maintain the
integrity of the glomerular filtration barrier and its reduced
production can lead to proteinuria. Renal damage can cause
hypertension and hypertension can aggravate proteinuria.
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and grade 3 or 4 proteinuria in 3% of all the patients. In a
phase II study of pazopanib involving 225 patients with
metastatic renal cell cancer, there was no mention of
proteinuria as an adverse event. However, in this report,
only adverse events occurring in greater than 10% of patients
were reported.21 In a phase III trial of pazopanib in patients
with advanced renal cell cancer, 435 patients were enrolled
and had an incidence of 9% proteinuria, with grade 3 or
above proteinuria in o1% of the patients.22 Cediranib, a
recently developed potent VEGF inhibitor, currently in
evaluation in phase III trials, has also been reported to cause
proteinuria in phase II trials. In a phase II study of recurrent
epithelial ovarian cancers, cediranib caused proteinuria in
30% of the patients within 2 weeks. However, none
developed high-grade proteinuria.23 These data reveal that
it is possible that newer TKIs may have reduced incidence of
development of proteinuria. However, they need to be viewed
with caution because of heterogeneity in reporting this
important adverse effect. At the very least, patients should
undergo urine protein/creatinine ratio testing on a second
morning void before and after receiving the drug. More long-
term information is needed regarding their side effects.
Biopsy findings. Reports of renal biopsies among patients
with proteinuria receiving TKIs are sparse. When reported,
the most common causative agent was bevacizumab.
Pathological findings have included 12 cases of TMA, two
cases of collapsing glomerulopathy, and isolated reports of
cryoglobulinemic and immune complex glomerulonephri-
tis.11 Details of the biopsy findings are listed in Table 3.
Thrombotic microangiopathy. TMA of the kidney is a
localized manifestation of several severe systemic illnesses
such as hypertensive emergency, scleroderma crisis, thrombo-
tic thrombocytopenic purpura, and so on. Its pathogenesis has
been primarily linked to endothelial damage. Inhibition of
VEGF with TKIs leads to endothelial damage that results in
local thrombosis as seen on biopsy. However, patients who
developed TMA following exposure to TKI only manifested as
renal dysfunction with low-grade proteinuria and did not have
significant systemic findings of grave illnesses as mentioned
earlier. Thus, there is a possibility of relative lack of correlation
of findings of renal biopsy to systemic manifestations.
Renal biopsy is an invasive test and appropriately not done
in all patients who develop proteinuria after exposure to
TKIs. As such these findings may not be generalizable to all
patients with proteinuria. However, as the severity of
proteinuria correlates with patient outcomes, selected
patients with high-grade proteinuria may be considered as
candidates to have a lower threshold for kidney biopsy to
better describe the renal manifestations of proteinuria with
TKI.
Hypertension. Hypertension has been reported with the
use of TKIs, including hypertensive crisis, which can be life
threatening. In their meta-analysis, Zhu et al.15 identified that
low-dose bevacizumab was associated with hypertension,
between 2.7 and 32% and 17.6 and 36% for the high-dose
group. Grade III hypertension developed in 8.7% and 16%
for low-dose and high-dose bevacizumab, respectively.15
Bevacizumab was found to be associated with a significant
increased risk of all grades of hypertension with RRs of 3.0
for low dose (95% CI: 2.2–4.2) and 7.5 for high dose (95%
CI: 4.2–13.4). In a recent review, Ranpura et al.24 evaluated
more than 12,000 patients with various tumors across several
studies specifically for high-grade hypertension with bevaci-
zumab. They found an overall incidence of all-grade
hypertension to be 23.6, with 7.9% being high grade (grade
3 or 4). The RR of developing high-grade hypertension was
calculated to be around 5.28 (95% CI: 4.15–6.71). These
findings were, however, dependent on the dose of bevacizu-
mab and the type of tumor. A similar meta-analysis of
sunitinib evaluating almost 5000 patients revealed an overall
incidence of hypertension to be 8.6–29.6%. Summary
incidence of high-grade hypertension was 6.8% (95% CI:
5.3–8.8%).25 Higher incidence of hypertension was also
noted in a phase II trial of the newer oral multi-TKI
cediranib.23 A total of 67% developed hypertension by day 3
of administration and 87% by the end of the study. More
than 43% developed grade III hypertension. Only advanced
age (457 years) was identified as an independent predictor
for the development of hypertension. Incidence of hyperten-
sion was uniformly around 30–40%, with a much lower
incidence of grade 3 or higher hypertension (3–4% in phase
II and III trials and up to 25% in phase I trial). Table 4
summarizes the current meta-analyses on the development of
hypertension and proteinuria with TKI.
Mechanisms in the development of hypertension. The
mechanism(s) of development of hypertension are far less
Table 2 | Grades of proteinuria and hypertension used for clinical trials
Grade I Grade II Grade III Grade IV Grade V
Proteinuria 1+ on dipstick or
0.15–1.0 g/24 h
2+ to 3+ on dipstick or
41.0–3.5 g/24 h
4+ on dipstick or
43.5 g/24 h
Nephrotic syndrome Death
Hypertension Asymptomatic, transient
(o24 h) increase by
420mmHg (diastolic) or
to 4150/100mmHg if
previously WNL;
intervention not indicated
Recurrent or persistent
(X24 h) or symptomatic
increase by 420mmHg
(diastolic) or to 4150/
100mmHg if previously
WNL; monotherapy may be
indicated
Requiring more than one
drug or more intensive
therapy than previously
Life-threatening
consequences (e.g.,
hypertensive crisis)
Death
Abbreviation: WNL, within normal limits.
Common Terminology Criteria for Adverse Events (v 3.0) Grading of Proteinuria and Hypertension in Cancer Trials.34
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understood than proteinuria. Although inhibition of VEGF
leads to significant proteinuria in animal models, the same
has not been shown for development of hypertension. To
further elucidate the mechanisms involved, Veronese et al.
evaluated several biochemical and physiological parameters
with the use of sorafenib. They measured plasma VEGF, total
catecholamines, epinephrine, norepinephrine, endothelin I,
urotensin II, renin, and aldosterone levels at baseline and
again after 3 weeks of therapy among patients enrolled in a
phase II randomized discontinuation clinical trial receiving
sorafenib.26 They also measured central aortic augmentation
index and aortic pulse wave velocity as index of arterial
stiffness. They found that none of the biochemical markers
were significantly elevated to explain development of
hypertension. However, there was a 30% increase in central
aortic augmentation index and 9% increase in aortic pulse
Table 3 | Renal biopsy findings reported in literature with use of TKIs
TKI Malignancy Biopsy findings
Bevacizumab,6 sunitinib18 Hepatocellular cancer, bronchoalveolar carcinoma, small-cell
lung cancer, metastatic ovarian cancer, malignant skin
hidradenoma
Thrombotic microangiopathy with widening of the
subendothelial space of glomerular capillaries,
duplication of the glomerular basement membranes with
cellular interposition, mesangiolysis, and extensive or
focal effacement of foot processes. Focal or diffuse
glomerular capillary thrombosis has been reported. In
addition, modest mesangial deposition of IgA has also
been seen
Bevacizumab6 Metastatic pancreatic cancer Collapsing glomerulopathy with features of thrombotic
microangiopathy
Bevacizumab29 Recurrent non-small-cell lung cancer Cryoglobulinemic vasculitisa
Bevacizumab30 Pancreatic cancer, renal cell cancer Immune complex-associated focal proliferative
glomerulonephritis: thickened capillary wall segmental
endocapillary hypercellularity with obliteration of
capillary lumina segmental karyorrhexis. In addition mild
segmental mesangial hypercellularity with slightly
increased matrix was also noted. On
immunofluorescence diffuse granular IgA deposits in the
glomerular capillary walls and mesangial areas, k- and l-
light chains, and mild fluorescence for IgG and IgM have
been identified
Bevacizumab31
Sorafenib32
Metastatic rectal leiomyosarcoma, metastatic renal cell cancer Acute interstitial nephritis with polynuclear infiltration in
some glomerular capillary walls in the setting of chronic
glomerulopathy
Bevacizumab33 Metastatic small-cell cancer of lung Crescentic glomerulonephritis: features of severe intimal
fibrosis of arteries, mild hyalinosis of arterioles, and wide
interstitial fibrosis associated with focal lymphocytic
infiltration and tubular atrophy. Immunofluorescence
showed mesangial granular IgM and C3 deposits and
segmental staining for fibrinogen in the crescents
Abbreviations: Ig, immunoglobulin; TKI, tyrosine kinase inhibitor.
aPathological findings not reported.
Table 4 |Meta-analyses evaluating proteinuria and hypertension with TKI
Study (reference) TKI N No. of studies Cancer type Proteinuria (RR) 95% CI HTN (RR) 95% CI
Zhu et al.15 Bevacizumab 1850 7 Severala 1.4 (low dose) 1.1–1.7 3 2.2–4.2
2.2 (high dose) 1.6–2.9 7.5 4.2–13.4
Ranpura et al.24 Bevacizumab 12,656 20 All cancersb NA NA 23.6 20.5–27.1
Wu et al.16 Bevacizumab 12,268 12 Severalc 4.79 2.7–8.4 NA NA
Zhu et al.25 Sunitinib 4999 13 Severald NA NA 21.6 18.7–24.8
Abbreviations: CI, confidence interval; CRC, colorectal cancer; HTN, hypertension; NA, not applicable; NSCLC, non-small-cell lung cancer; RCC, renal cell cancer; RR, relative risk;
TKI, tyrosine kinase inhibitor.
aRCC, CRC, breast, NSCLC, and malignant mesothelioma.
bUnderlying malignancies included CRC (seven studies), NSCLC (four studies), breast cancer (three studies), pancreatic cancer (three studies), RCC (three studies), and
malignant mesothelioma (one study).
cCRC (six studies), NSCLC (two studies), breast cancer (three studies), pancreatic cancer (two studies), RCC (two studies), and malignant mesothelioma (one study).
dRCC, SCLC, gastrointestinal stromal tumor, gastric cancer, and urothelial carcinoma.
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wave velocity. These changes do not, however, explain how
hypertension could develop in a matter of days. One of the
leading explanations provided has been the nitric oxide (NO)
generation hypothesis. It has been noted that VEGF exerts its
angiogenic effects by enhancing the transcription of en-
dothelial NO synthase.27 Endothelial NO has vasodilatory
properties, and inhibition of VEGF may lead to a decrease in
NO and a resultant increase in the incidence of hypertension.
The potential role of VEGF with regard to its vasodilatory
properties was further explored in the Vascular endothelial
growth factor in Ischemia for Vascular Angiogenesis trial
wherein 178 patients with stable exertional angina, unsuitable
for standard revascularization, were randomized to receive
either placebo or low- or high-dose recombinant human
VEGF intracoronary, followed by intravenous administration
on days 3, 6, and 9.28 Significant decline in blood pressure
was seen more so with the high-dose infusion of recombinant
human VEGF. This appeared to have clinical significance too,
as patients had a significant improvement in their angina
scores, as well as quality of life. Unfortunately, these blood
pressure-lowering effects were only transient and required
intravenous infusions. Therapeutic implications for potential
in treatment of uncontrolled hypertension exist but need to
be balanced by the angiogenic effects, which may sometimes
be undesirable. Further oral methods of delivery need to be
devised for it to be a viable long-term treatment for
hypertension.
Extrarenal side effects of TKI. Several unique extrarenal
side effects of TKIs have been reported in the literature as
opposed to other chemotherapeutic agents. These include,
but are not limited to, cardiac ischemia or infarct,
gastrointestinal perforation, thrombosis and thromboem-
bolic events, reversible posterior leukoencephalopathy, and
impaired wound healing. Various tubular disorders such as
Fanconi syndrome, renal tubular acidosis, and nephrogenic
diabetes insipidus may be seen with the use of chemother-
apeutic agents. If identified in the clinical setting of TKI use,
it may be difficult to distinguish from paraneoplastic effects
of the underlying malignancy.
Management of proteinuria and hypertension
Proteinuria and hypertension are independent risk factors for
adverse cardiovascular outcomes and progression of renal
disease. With increasing survival in cancer patients, it is
imperative that these side effects are recognized and managed
appropriately. Evidence-based guidelines for management of
proteinuria and hypertension with TKIs are lacking. For
example, data on proteinuria have been collected using the
NCI classification; this system uses definitions not commonly
used by nephrologists. Further, several of the trials excluded
patients with preexisting proteinuria and uncontrolled hyper-
tension, limiting evaluation of probability of developing these
side effects in such patient groups. However, current
recommendations are to screen for the presence of protei-
nuria and hypertension before initiation and before each
administration of cycled therapy or on a periodic basis when
oral daily TKIs are used. Proteinuria may not be a reliable
marker of TMA. For example, biopsy findings of severe TMA
do not correlate well with proteinuria. In fact, several of those
patients had only grade I or II proteinuria. However, the
paucity of biopsy data makes this clinical correlation difficult
and underscores the need for further studies. However, in
practice, if there is persistent severe proteinuria, one must
have a low threshold for renal biopsy, and if TMA is evident,
consider risks and benefits for stopping TKIs and choosing
alternate chemotherapeutic regimen. This may not be
possible in situations in which TKIs are being used as a last
resort for recurrent or advanced cancer. Additional discus-
sion with patients regarding risks and benefits of continua-
tion of these agents in such situations may be needed. As
proteinuria may be frequently associated with hypertension,
the use of angiotensin-converting enzyme inhibitors as a
treatment option can be considered to lower proteinuria.
Angiotensin-converting enzyme inhibitors also are the
suggested first-line agents for patients who develop hyper-
tension even in the absence of proteinuria. Although renin
and angiotensin levels were not noted to be significantly
elevated with VEGF inhibition, the favorable endothelial
effects of angiotensin-converting enzyme inhibitors/angio-
tensin receptor blockers make them an attractive first-line
agent. Whether other agents such as diuretics, calcium
Screen for proteinuria
before initiation of TKI
Screen for proteinuria periodically
or before each administration of TKI
If high-grade proteinuria, hypertensive crisis or microscopic
hematuria, consider renal biopsy vs. continuation of TKI,
evaluating risks and benefits especially in circumstances
when alternative therapies are lacking
HTN+
Treat with
ACE-I or ARB
Quantify proteinuria/check UA
HTN–
Initiate TKI
Identify cause and
treat proteinuria
Consider alternative treatment
if one available
Evaluate risks
and benefits
+–
Persistent
Persistent
Figure 2 |An algorithm for screening and management of
proteinuria and hypertension with tyrosine kinase inhibitors
(TKIs). ACE-I, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; HTN, hypertension; UA, urinalysis.
See text for details.
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channel blockers, or b-blockers provide similar or additional
benefit is unknown and may be considered as viable
alternatives. A suggested schema for management of hyper-
tension and proteinuria with the use of TKIs is provided in
Figure 2. This approach, however, needs to be confirmed for
its efficacy in prospective trials.
CONCLUSIONS
TKIs are an effective antineoplastic treatment option for
treatment of several advanced cancers with relatively good
success. There has been a significant investment in further
development of these drugs given their impressive therapeu-
tic potential. We expect to see the use of these medications to
be more widespread in the near future. Recognizing the side
effects of hypertension and proteinuria is important to avoid
unnecessary diagnostic testing.
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